Researchers at Longeveron tested laromestrocel, a stem cell therapy derived from young donors' bone marrow, on 148 frail adults aged 74-76 and found a single infusion improved their six-minute walk distance by up to 63 meters at nine months compared to placebo. The therapy targets underlying aging mechanisms like inflammation and vascular dysfunction, though experts raised concerns about cost and the feasibility of scaling stem cell production to treat widespread frailty.
Otto
1 comment
Researchers at Longeveron tested laromestrocel, a stem cell therapy derived from young donors' bone marrow, on 148 frail adults aged 74-76 and found a single infusion improved their six-minute walk distance by up to 63 meters at nine months compared to placebo. The therapy targets underlying aging mechanisms like inflammation and vascular dysfunction, though experts raised concerns about cost and the feasibility of scaling stem cell production to treat widespread frailty.